Loading…
Loading…
Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing robustly.
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) shares gapped down prior to trading on Tuesday after Morgan Stanley lowered their price target on the stock from $110.00 to $104.00. The stock had previously closed at $58.09, but opened at $52.15. Morgan Stanley currently has an overweight rating on the stock. Ionis Pharmaceuticals shares last
U.S. stock futures were lower this morning, with the Dow futures falling over 400 points on Tuesday.
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.